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A recombinant human anti-herpes simplex virus monoclonal IgG1 antibody and the corresponding Fab and F(ab*)2 frag-
ments were tested for efficacy in preventing vaginal transmission of HSV-2 infection in a well-established mouse model for
genital herpes. IgG1 , Fab, and F(ab*)2 were approximately equally protective; vaginal delivery of 1–5 ng provided approxi-
mately 50% protection, and vaginal delivery of 400 ng completely protected mice from genital herpes infection (P ! 0.001).
These results suggest that topical applications of human monoclonal antibodies may be useful in developing new methods
for preventing sexually transmitted disease. q 1996 Academic Press, Inc.
Despite widespread promotion of condoms and other pathogens has become straightforward (7–9). Genera-
tion of a human anti-HSV MAb, HSV8, has recently beenmethods for preventing unintended pregnancies and sex-
ually transmitted disease (STD), in the United States described (8, 10); this MAb binds glycoprotein D and is
a potent neutralizer in vitro. Systemic delivery of HSV8alone there are an estimated 3 million unintended preg-
nancies and 12 million new cases of STD each year (see has been shown to protect nude mice from intradermal
and corneal transmission of HSV-1 (10). We report here1). These pandemics of unintended pregnancies and
STD infections indicate an urgent need for improved the results of efficacy trials testing topical delivery of
HSV8 for preventing vaginal transmission of HSV-2 in amethods of prophylactic contraception (2). Since antibod-
ies are natural protective agents abundant in mucus se- mouse model (3, 11). We also tested Fab and F(ab*)2
fragments derived from this monoclonal antibody.cretions, and since they are potent and specific, mono-
clonal antibodies (MAbs) have recently been suggested Whole HSV8 antibody (10), was produced in CHO cells
for topical application to genital surfaces for contracep- maintained in CHO serum-free medium (GIBCO-BRL;
tion and the prevention of STDs (1, 3). Indeed, using Gaithersburg, MD); antibody was purified from the super-
mouse MAbs, we have recently confirmed that vaginal natant by affinity chromatography with an immobilized
delivery of anti-rabbit sperm MAbs to the rabbit vagina chicken anti-human antibody according to standard tech-
can prevent pregnancy in the rabbit (4). Similarly, we niques (12). Human IgG1 purified from myeloma serum
have shown that topical delivery of a mouse anti-herpes was obtained from Chemicon (Temecula, CA) and used
simplex virus type 2 (HSV-2) MAb can prevent transmis- as a control. Proteolytic digestions of HSV8 to obtain Fab
sion of HSV-2 infection in the mouse via the vagina (3), and F(ab*)2 fragments were carried out as described by
as well as prevent transmission via genital skin and the Harlow and Lane (12). Electrophoresis performed under
rectum (unpublished results). For human applications, nondenaturing conditions confirmed the purity of these
human MAbs may be desirable to reduce the likelihood fragments (not shown). To increase the susceptibility of
of undesirable immune responses. With the advent of the mice to vaginal transmission of HSV-2 (11), we treated
ability to clone human MAbs from combinatorial libraries female, 8- to 12-week-old C57Bl/6 mice (Harlan; Freder-
(reviewed in 5, 6), the production of human MAbs against ick, MD) subcutaneously (100 ml, 2.5 mg/dose) with a
long-acting progestin (Depo-Provera; Upjohn, Kalama-
zoo, MI) 7 days prior to the day of viral inoculation. Anti-
1 Current address: ReProtect LLC, Baltimore, MD 21286. bodies or antibody fragments were delivered in 10 ml of
2 To whom correspondence and reprint requests should be ad-
phosphate-buffered saline to the vagina approximatelydressed at Thomas C. Jenkins, Department of Biophysics, The Johns
20 sec prior to delivery of a 10 ml HSV-2 inoculum con-Hopkins University, 3400 N. Charles Street, Baltimore, MD 21218. Fax:
(410) 516-6597. taining 105 TCID50 . This inoculum is approximately 10
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ID50 when infection is assayed by observation of visible
lesions and 30 ID50 when assayed by culture of vaginal
lavage (see below). HSV-2, strain G, was obtained from
Virotech International (Rockville, MD). The sample was
thawed, refrozen in aliquots at 0707, and thawed and
diluted with media (Bartels Tissue Culture Refeeding Me-
dium; Baxter) just prior to use. These thawed aliquots
had a titer of 5 1 108 TCID50/ml on human newborn
diploid fibroblasts (Baxter; Issaquah, WA). Mice were as-
sessed for infection by observation of visible lesions and
by detection of viral shedding from the vagina as deter-
mined by culture of vaginal lavages (3) taken 3 days after
inoculation (infected animals shed peak amounts of virus
on Day 3; unpublished results). Mice were examined
daily for 17 days after viral inoculation for visible lesions
(perineal hair loss, reddening, and swelling); mice dis-
playing lesions were sacrificed immediately to prevent
undue suffering. Vaginal lavages were obtained by pi-
petting 20 ml of medium (Bartels Tissue Culture Refeed-
ing Medium; Baxter) in and out of the vagina 10 times;
lavages were diluted to 0.1 ml, and placed on target cells
(human newborn foreskin diploid fibroblasts; Baxter). Cy-
topathic effect (CPE) was scored 2 days later. A total of
168 mice were inoculated. Statistical significance was
determined by Fisher’s exact test (13).
Figure 1 illustrates the efficacy of the three molecules
for preventing vaginal transmission of HSV-2 infection as
assayed by detection of vaginally shed virus (Fig. 1A)
FIG. 1. Percentage infected animals as a function of vaginal dose
and by observation of visible lesions (Fig. 1B). At the of human anti-HSV monoclonal IgG1 , Fab, F(ab*)2 . (A) Percentage of
higher doses, IgG1 , Fab, and F(ab*)2 were approximately mice shedding virus (7 £ n £ 10; n  18 for phosphate-buffered saline
with no antibody; PBS). n  10 in some instances because someequally effective on a mass basis, suggesting a slightly
animals could not be scored due to fungal overgrowth of the targetlower potency for the Fab on a molar basis. At lower
cells. (B) Percentage of mice with visible lesions (n  10, except fordoses, although the data are subject to experimental
PBS, n  18). For clarity, standard deviation is not shown; for all data
scatter, the Fab appeared to be up to an order of magni- points (A and B) the standard deviation £15%.
tude less effective than IgG on a molar basis. Complete
protection against vaginal transmission of HSV-2 infec-
tion was achieved at doses of 400 ng antibody or anti- a dramatic functional difference between the human IgG
and Fab in this study is probably due to steric constraintsbody fragment (P  0.001, compared to human IgG1 or
PBS controls), while approximately 1–5 ng provided 50% that prevent multivalent binding; electron micrographs by
Stannard et al. suggest that glycoprotein D is deeplyprotection.
To our knowledge, these experiments are the first to recessed in the virion’s glycocalyx (10 nm; 16).
Since human MAb Fab fragments completely pro-demonstrate the protective efficacy of topical passive
immunization with a human MAb or Fab fragment for tected mice from HSV-2 infection, it appears that effector
functions mediated by Fc , such as complement and anti-preventing infection by a human STD pathogen in vivo.
This MAb is one of the most potent anti-HSV MAbs de- body-dependent cellular cytotoxicity (ADCC), are not re-
quired for topically applied protection. In addition, sincescribed to date. Similar to the anti-HSV mouse MAb (III-
174; 14) used in our previous study (3), this human MAb antibody alone was capable of preventing infection,
these results suggest that vaccines that succeed in stim-is believed to neutralize by a postattachment mechanism
(8); however, this human MAb is approximately 10 times ulating a strong mucosal vaginal antibody response, in-
dependent of a cell-mediated response, may be capablemore potent than III-174, which required 10 ng to provide
50% protection (3). of preventing vaginal transmission of genital herpes.
The potency and specificity of human MAbs may helpIt is noteworthy that Fab was nearly as potent as IgG.
Multivalent binding can potentially greatly increase the create improved methods for preventing STDs. Indeed,
the human MAb used in this study is on the order offunctional affinity, or avidity, of an antibody relative to
the affinity of a monovalent Fab fragment (15), if steric 1000 times more potent for preventing HSV-2 infection
in the mouse than nonoxynol-9, the spermicidal deter-constraints allow for multivalent binding. The absence of
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United Nations. Cairo, Egypt. September 5–13, 1994. Sectiongent now used in most vaginal contraceptives. The dura-
12.10.tion of protection by a topically applied monoclonal is
3. Whaley, K. J., Zeitlin, L., Barratt, R. A., Hoen, T. E., and Cone, R. A.,
limited by the residence time of antibodies in the vagina. J. Infect. Dis. 169, 647–649 (1994).
The residence time in the human vagina is unknown; 4. Castle, P. E., Whaley, K. J., Hoen, T. E., Moench, T. R., and Cone,
R. A., Biol. Reprod., in press.however, we found the residence half-life in the mouse
5. Burton, D. R., and Barbas, C. F., Adv. Immunol. 57, 191–280 (1994).vagina to be approximately 5 hr (17). Since the mouse
6. Winter, G., Griffiths, A. D., Hawkins, R. E., and Hoogenboom, H. R.,vagina has about 20 times the surface area-to-volume Annu. Rev. Immunol. 12, 433–455 (1994).
ratio of the human vagina, we expect that several days 7. Williamson, R. A., Burioni, R., Sanna, P. P., Partridge, L. J., Barbas,
C. F., and Burton, D. R., Proc. Natl. Acad. Sci. USA 90, 4141–of protection may be provided by a single dose of anti-
4145 (1993).body in humans. For longer-term protection, vaginal de-
8. Burioni, R., Williamson, R. A., Sanna, P. P., Bloom, F. E., and Burton,vices that provide sustained release of antibodies may
D. R., Proc. Natl. Acad. Sci. USA 91, 355–359 (1994).
protect for weeks to months; we found antibody-releasing 9. Sanna, P. P., Williamson, R. A., DeLogu, A., Bloom, F. E., et al.,
vaginal devices to be capable of releasing antibody in Proc. Natl. Acad. Sci. USA 92, 6439–6443 (1995).
10. Sanna, P. P., DeLogu, A., Williamson, R. A., Hom, Y. L., et al., Virologythe mouse vagina for as long as a month (18) and capable
215, 101–106 (1996).of protecting mice from a vaginal HSV-2 inoculum for as
11. Whaley, K. J., Barratt, R. A., Zeitlin, L., Hoen, T. E., and Cone, R. A.,long as a week (19). J. Infect. Dis. 168, 1009–1011 (1993).
The advent of methods for producing antigen-specific 12. Harlow, E., and Lane, D., Antibodies: A Laboratory Manual. Cold
Spring Harbor Laboratory, Cold Spring Harbor, NY, 1988.human MAbs by screening combinatorial libraries (5), for
13. Matthews, D. E., and Farewell, V., Using and Understanding Medi-enhancing their affinity in vitro (20, 21), and for producing
cal Statistics, pp. 20–38. Karger, Basel, Switzerland, 1985.these MAbs in plants at a fraction of the cost of traditional
14. Para, M. F., Parish, M. L., Noble, A. G., and Spear, P. G., J. Virol.
techniques (22, 23) makes new methods for preventing 55, 483–488 (1985).
unintended pregancies and STDs both technically and 15. Crothers, D. M., and Metzger, H., Immunochemistry 9, 341–357
(1972).economically feasible.
16. Stannard, L. M., Fuller, A. O., and Spear, P. G., J. Gen. Virol. 68,
715–725 (1987).
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